Clinical Characteristics and Prognosis of Primary Pulmonary Lymphoma.
10.19746/j.cnki.issn.1009-2137.2025.02.012
- Author:
You-Fan FENG
1
;
Yuan-Yuan ZHANG
2
;
Xiao Fang WEI
1
;
Qi-Ke ZHANG
1
;
Li ZHAO
3
;
Xiao-Qin LIANG
4
;
Yuan FU
1
;
Fei LIU
1
;
Yang-Yang ZHAO
1
;
Xiu-Juan HUANG
1
;
Qing-Fen LI
1
Author Information
1. Department of Hematology, Gansu Provincial Hospital,Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
2. The First School of Clinical Medicine, Gansu University of Chinese Medicine, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
3. The First School of Clinical Medicine, Lanzhou University,Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
4. Department of Pathology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
- Publication Type:Journal Article
- Keywords:
primary pulmonary lymphoma;
clinical characteristics;
prognosis
- MeSH:
Humans;
Middle Aged;
Male;
Female;
Adult;
Prognosis;
Aged;
Lung Neoplasms/therapy*;
Retrospective Studies;
Neoplasm Staging;
Lymphoma/therapy*;
Lymphoma, Large B-Cell, Diffuse
- From:
Journal of Experimental Hematology
2025;33(2):387-392
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics and prognosis of primary pulmonary lymphoma (PPL).
METHODS:The clinical data of 17 patients with PPL admitted to Gansu Provincial Hospital from January 2013 to June 2023 were collected, and their clinical characteristics and prognosis were retrospectively analyzed and summarized.
RESULTS:The median age of the 17 patients was 56 (29-73) years old. There were 8 males and 9 females. According to Ann Arbor staging system, there were 9 patients with stage I-II and 8 patients with stage III-IV. There were 14 patients with IPI score of 0-2 and 3 patients with IPI score of 3-4. All 17 patients had symptoms at the initial diagnosis, most of the first symptoms were cough, and 6 patients had B symptoms.Among the 17 patients, there were 8 cases of diffuse large B-cell lymphoma (DLBCL), 5 cases of mucosa-associated lymphoid tissue (MALT) lymphoma, 1 case of gray zone lymphoma (GZL), and 3 cases of Hodgkin's lymphoma (HL). 15 patients received chemotherapy, of which 3 cases received autologous hematopoietic stem cell transplantation(ASCT) and 3 cases received radiotherapy; 2 patients did not receive treatment. The median number of chemotherapy courses was 6(2-8). The short-term efficacy was evaluated, 12 patients achieved complete remission (CR) and 3 patients achieved partial remission (PR). The age, pathological subtype, sex, Ann Arbor stage, β2-microglobulin(β2-MG) level, lactate dehydrogenase(LDH) level were not correlated with CR rate (P >0.05), while IPI score was correlated with recent CR rate (P < 0.05 ). The median follow-up time was 31(2-102) months. One of the 12 CR patients died of COVID-19, and the rest survived. Among the 3 patients who did not reach CR, 1 died after disease progression, while the other 2 survived. One of the 2 untreated patients died one year after diagnosis. Both the median progression-free survival (PFS) time and overall survival (OS) time of the 17 patients were both 31 (2-102) months.
CONCLUSION:The incidence of PPL is low, and the disease has no specific clinical manifestations, which is easily missed and misdiagnosed. The pathological subtypes are mainly MALT lymphoma and DLBCL, and the treatment is mainly combined chemotherapy. The IPI score is related to the treatment efficacy.
